金屬β-內(nèi)酰胺酶屬于B類β-內(nèi)酰胺酶，可廣泛水解除單環(huán)外的其余β-內(nèi)酰胺類抗生素。產(chǎn)金屬β-內(nèi)酰胺酶的菌株常常表現(xiàn)為多重耐藥，增加了臨床抗感染治療的難度。產(chǎn)金屬β-內(nèi)酰胺酶細菌的治療藥物主要包括基于氨曲南的藥物聯(lián)合治療、頭孢地爾、新型β-內(nèi)酰胺酶抑制劑聯(lián)合治療和基于傳統(tǒng)抗生素類結(jié)構(gòu)研發(fā)的新型抗生素?；诖?，概述了產(chǎn)金屬β-內(nèi)酰胺酶細菌的治療藥物的研究進展，以期為產(chǎn)金屬β-內(nèi)酰胺酶細菌感染的臨床治療提供參考。

Metal β-lactamases belong to class B β-lactamases, and can extensively hydrolyze all β-lactam antibiotics except for monocyclic antibiotics. Metal-producing β-lactamase strains often exhibit multiple drug resistance, increasing the difficulty of clinical anti-infection treatment. Drugs in treatment of metal-producing β-lactamase bacteria mainly include combination drug based on amtreonam, cefiderocol, novel drugs β-lactam combination with β-lactamase inhibitors, and newly developed antibiotics based on traditional antibiotic structures. Therefore, this article summarizes research progress on drugs in treatment of metal-producing β-lactamase bacteria, to provide references for clinical treatment of bacterial infections caused by metal-producing β-lactamase bacteria.

東莞市社會發(fā)展科技面上項目（20221800900152）